Innocan reports 90.9% gross margin as second-quarter revenue falls 25.06%

Aug 31, 2026 20:01 (20d ago)

Verifying

Innocan Pharma reported second-quarter 2026 consolidated financial results and brand performance.
Revenue reached US$5.25 million, down 25.06% year over year.
B.I. Sky retained VALITIC's Amazon Best Seller badge and Amazon's Choice recognition.

The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.